Health
Health Experts Debate Vaccine Messaging and Rare Disease Treatments
Experts debate the effectiveness of vaccine messaging strategies, with some suggesting a more nuanced approach. Meanwhile, a biotech company faces a critical moment in its cancer drug development.
Coverage timeline — 5 articles
STAT News
Some experts say public health messaging would be more credible if it focused less on measles deaths and acknowledged that most children survive.
2026-10-21 08:30 UTC
STAT News
Mark Cuban's Cost Plus Drugs says it can reduce manufacturing costs for custom rare disease drugs and n-of-1 gene therapies.
2026-10-21 08:30 UTC
STAT News
“Committing a Type 1 error does not reflect poorly on the quality of the science done,” writes Mark Louie F. Ramos
2026-10-21 08:30 UTC
STAT News
“As measles outbreaks spread in the U.S., it may be time to learn how other countries get their outbreaks under control,” writes Raj Panjabi.
2026-10-21 08:30 UTC
STAT News
After a quarter century of work, the German biotech Immatics is facing a pivotal moment as it awaits Phase 3 results for its lead candidate in melanoma.
2026-10-21 08:30 UTC